Acta Med. 2025, 68: 21-25

https://doi.org/10.14712/18059694.2025.14

Relationship Between XRCC1 Arg399gln Polymorphism and Risk of Luminal Subtype Breast Cancer in Bali, Indonesia

I Wayan Gede Sutadarmaa,b, I Gede Putu Supadmanabaa,bID, Putu Anda Tusta AdiputracID, Anggi Amanda Triana DevydID, Anak Agung Bagus Putra Indrakusumad, I Gede Aswin Parisya SasmanadID

aDepartment of Biochemistry, Faculty of Medicine, Udayana University, Indonesia
bDepartment of Clinical Nutrition, Faculty of Medicine, Udayana University – Prof. Dr. IGNG Ngoerah General Hospital, Denpasar, Indonesia
cDivision of Surgical Oncology, Department of Surgery, Faculty of Medicine, Udayana University – Prof. Dr. IGNG Ngoerah General Hospital, Denpasar, Indonesia
dFaculty of Medicine, Udayana University, Indonesia

Received December 19, 2024
Accepted April 24, 2025

References

1. Sasmana I, Putri P, Dewi N, Supadmanaba I, Wihandani D. Current Development of Virotherapy in Breast Cancer: A Brief Review. Acta Med Bulg. 2024 Dec; 51(4): 86–94. Available from: https://www.sciendo.com/article/10.2478/amb-2024-0084.
2. Parada HJ, Sun X, Tse CK, Olshan AF, Troester MA. Lifestyle Patterns and Survival Following Breast Cancer in the Carolina Breast Cancer Study. Epidemiology. 2019 Jan; 30(1): 83–92. <https://doi.org/10.1097/EDE.0000000000000933> <PubMed>
3. White AJ, Bradshaw PT, Hamra GB. Air pollution and Breast Cancer: A Review. Curr Epidemiol Rep. 2018 Jun; 5(2): 92–100. <https://doi.org/10.1007/s40471-018-0143-2> <PubMed>
4. Mahvi DA, Liu R, Grinstaff MW, Colson YL, Raut CP. Local Cancer Recurrence: The Realities, Challenges, and Opportunities for New Therapies. CA Cancer J Clin. 2018 Nov; 68(6): 488–505. <https://doi.org/10.3322/caac.21498> <PubMed>
5. Narod SA. Personalised medicine and population health: breast and ovarian cancer. Hum Genet. 2018 Oct; 137(10): 769–78. <https://doi.org/10.1007/s00439-018-1944-6>
6. Cain EH, Saha A, Harowicz MR, Marks JR, Marcom PK, Mazurowski MA. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set. Breast Cancer Res Treat. 2019 Jan; 173(2): 455–63. <https://doi.org/10.1007/s10549-018-4990-9> <PubMed>
7. Doren A, Vecchiola A, Aguirre B, Villaseca P. Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations. Climacteric. 2018 Dec; 21(6): 529–35. <https://doi.org/10.1080/13697137.2018.1514006>
8. Fragomeni SM, Sciallis A, Jeruss JS. Molecular subtypes and local-regional control of breast cancer. Surg Oncol Clin N Am. 2018; 27(1): 95–120. <https://doi.org/10.1016/j.soc.2017.08.005> <PubMed>
9. Anurag M, Jaehnig EJ, Krug K, et al. Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 Nov; 12(11): 2586–605. <https://doi.org/10.1158/2159-8290.CD-22-0200> <PubMed>
10. Ali R, Alblihy A, Toss MS, et al. XRCC1 deficient triple negative breast cancers are sensitive to ATR, ATM and Wee1 inhibitor either alone or in combination with olaparib. Ther Adv Med Oncol. 2020; 12: 1–14. <https://doi.org/10.1177/1758835920974201> <PubMed>
11. Wright G, Sonavane M, Gassman NR. Activated stat3 is a novel regulator of the xrcc1 promoter and selectively increases xrcc1 protein levels in triple negative breast cancer. Int J Mol Sci. 2021 Jun; 22(11): 5475. <https://doi.org/10.3390/ijms22115475> <PubMed>
12. Datkhilea KD, Gudur RA, Bhosale SJ, et al. Impact of Interaction between Single Nucleotide Polymorphism of XRCC1, XRCC2, XRCC3 with Tumor Suppressor Tp53 Gene Increases Risk of Breast Cancer: A Hospital Based Case-Control Study. Asian Pac J Cancer Prev. 2023; 24(9): 3065–75. <https://doi.org/10.31557/APJCP.2023.24.9.3065> <PubMed>
13. Eckelmann BJ, Bacolla A, Wang H, et al. XRCC1 promotes replication restart, nascent fork degradation and mutagenic DNA repair in BRCA2-deficient cells. NAR Cancer. 2020 Aug; 2(3): zcaa013. <https://doi.org/10.1093/narcan/zcaa013> <PubMed>
14. Sastroasmoro S, Ismael S. Dasar-Dasar Metodologi Penelitian Klinis Edisi ke-5, Sagung Seto. 2018. 373 p.
15. Moghaddam AS, Nazarzadeh M, Moghaddam HS, et al. XRCC1 gene polymorphisms and breast cancer risk: A systematic review and meta- analysis study. Asian Pac J Cancer Prev. 2016; 17: 323–5. <https://doi.org/10.7314/APJCP.2016.17.S3.323>
16. Zhu G, Wang L, Guo H, et al. DNA Repair Genes XRCC1 and ERCC1 Polymorphisms and the Risk of Sporadic Breast Cancer in Han Women in the Gansu Province of China. Genet Test Mol Biomarkers. 2015 Jul; 19(7): 387–93. <https://doi.org/10.1089/gtmb.2015.0001>
17. Mills M, Liveringhouse C, Lee F, et al. The prevalence of luminal B subtype is higher in older postmenopausal women with ER+/HER2− breast cancer and is associated with inferior outcomes. J Geriatr Oncol. 2021 Mar; 12(2): 219–26. <https://doi.org/10.1016/j.jgo.2020.08.007> <PubMed>
18. Zhang L, Huang Y, Feng Z, et al. Comparison of breast cancer risk factors among molecular subtypes: A case-only study. Cancer Med. 2019 Apr; 8(4): 1882–92. <https://doi.org/10.1002/cam4.2012> <PubMed>
19. Akhzari VS, Asgharpour-Dil F, Shoja M, et al. The alterations of XRCC1 gene’s polymorphism with a different SNP is involved in breast cancer. Bali Med J. 2018; 7(3): 593–7. <https://doi.org/10.15562/bmj.v7i3.942>
20. Orrantia-Borunda E, Anchondo-Nuñez P, Acuña-Aguilar LE, Gómez-Valles FO, Ramírez-Valdespino CA. Subtypes of Breast Cancer. In: Breast Cancer [Internet]. Brisbane (AU): Exon Publications, 2022 Aug 6; Chapter 3.
21. Li Q, Ma R, Zhang M. XRCC1 rs1799782 (C194T) polymorphism correlated with tumor metastasis and molecular subtypes in breast cancer. Onco Targets Ther. 2018; 11: 8435–44. <https://doi.org/10.2147/OTT.S154746> <PubMed>
22. Bu T, Liu L, Sun Y, Zhao L, et al. XRCC1 Arg399Gln polymorphism confers risk of breast cancer in American population: A meta-analysis of 10846 cases and 11723 controls. PLoS One. 2014; 9(1): 1–9.
23. Floris M, Sanna D, Castiglia P, et al. MTHFR, XRCC1 and OGG1 genetic polymorphisms in breast cancer: A case-control study in a population from North Sardinia. BMC Cancer. 2020 Mar; 20(1): 234. <https://doi.org/10.1186/s12885-020-06749-w> <PubMed>
24. Zhao Y, Xie Y, Jia D, Ma C, Wei D, Zhang X. Original Article Application of gene polymorphisms to predict the sensitivity of patients with locally advanced non-small cell lung cancer undergoing chemoradiotherapy [Internet]. Vol. 13, Am J Transl Res. 2021. Available from: www.ajtr.org.
25. Afifi N, Barrero CA. Understanding Breast Cancer Aggressiveness and Its Implications in Diagnosis and Treatment. J Clin Med. 2023; 12(4): 10–2. <https://doi.org/10.3390/jcm12041375> <PubMed>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive